జర్నల్ ఆఫ్ ఎయిడ్స్ & క్లినికల్ రీసెర్చ్

Is Prime Boost Strategy a Promising Approach in HIV Vaccine Development?

Abstract

Ashwini Shete, Madhuri Thakar, Mehendale SM and Paranjape RS

Since the discovery of HIV vaccine three decades back, the quest for HIV vaccines has remained unquenched. There has been a transition of preferred approaches from candidates capable of inducing neutralizing antibody (Nab) or cytolytic T cell (CTL) response to vaccines that can induce broad spectrum responses. Heterologous prime boost strategy is believed to induce broad spectrum immunity of higher magnitude and breadth to effectively counter HIV diversity and hence is being studied extensively in the HIV vaccine field. It is important to understand factors affecting the immune responses generated by the prime-boost regimens to get leads for developing effective regimens. This review focuses on the results of completed clinical trials based on the three most frequently used prime-boost regimens, vector (ALVAC)/protein, DNA/vector (MVA) and DNA/vector (Ad5). It will also discuss probable protective immunological responses responsible for efficacy of the vaccine and role of prime boost strategy in eliciting them.